Clinical Trials Logo

Clinical Trial Summary

Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating synaptic damage that correlates with cognitive decline in AD patients. Transcranial Direct Current Stimulation (tDCS) is a safe, non-invasive, non-painful electrical stimulation of the brain that is shown to act as a primer at the synaptic level when administered along with behavioral therapy, mostly involving language, learning and memory. Previous studies have shown that tDCS over the left angular gyrus (AG) improves language associative learning in the elderly through changes in functional connectivity between the AG and the hippocampus. The investigators' previous clinical trial on the effects of tDCS in neurodegenerative disorders has also shown augmented effects of lexical retrieval for tDCS. In the present study the investigators will compare the effects of active vs. sham tDCS over the AG-an area that is part of the default mode network but also a language area, particularly important for semantic integration and event processing-in two predominant AD variants: probable AD with amnesic phenotype (amnesic/typical AD) and probable AD with non-amnesic (language deficit) phenotype also described as logopenic variant PPA with AD pathology (aphasic/atypical AD). The investigators aim to: (1) determine whether active high-definition tDCS (HD-tDCS) targeting the left AG combined with a Word-List Learning Intervention (WordLLI) will improve verbal learning; (2) identify the changes in functional connectivity between the stimulated area (AG) and other structurally and functionally connected areas using resting-state functional magnetic resonance imaging; (3) identify changes in the inhibitory neurotransmitter GABA at the stimulation site using magnetic resonance spectroscopy. Furthermore, the investigators need to determine the characteristics of the people that may benefit from the new neuromodulatory approaches. For this reason, the investigators will evaluate neural and cognitive functions as well as physiological characteristics such as sleep, and will analyze the moderating effects on verbal learning outcomes. Study results can help provide treatment alternatives as well as a better understanding of the therapeutic and neuromodulatory effects of tDCS in AD, thus improving patients' and caregivers' quality of life.


Clinical Trial Description

The investigation implements a double-blind, sham-controlled, within-subject, cross-over design that allows for the evaluation of the cognitive and neural effects of word-list learning as modulated by tDCS compared to sham stimulation. Participants in all groups will receive word-list learning intervention (WordLLI)+ High-Definition tDCS (HD-tDCS) or WordLLI+ sham in Period 1 or 2, randomized for the Period 1 stimulation condition. Each learning Period will last 2 weeks, with 5 learning sessions per week (for a total of 10 learning sessions per Period) with a 3-month (stimulation-free) wash-out period between the two Periods. The intensity, total number of learning sessions and number of learning items is consistent with most other tDCS studies in neurodegenerative disorders and the investigators have used this design successfully over the past 7 years in neurodegenerative disorders (PPA, mild AD). Stimulation is implemented every weekday to take advantage of the long-term potentiation induced by tDCS as found in early multi-session studies. A tDCS-only condition (without any intervention) is not implemented in this design because no study to date has shown improvement on motor, cognitive, or language performance after anodal tDCS-only for 2 or even more weeks. After each period the investigators will perform 1-month and 3-month follow-up sessions for evaluation purposes. For those participants who are long-distance, at the 1-month time point only the investigators may use a video conferencing tool such as GoToMeeting to administer the assessments. This is to mitigate the costs of travel for a short appointment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04122001
Study type Interventional
Source Johns Hopkins University
Contact Kyrana Tsapkini, PhD
Phone 410-736-2940
Email tsapkini@jhmi.edu
Status Recruiting
Phase N/A
Start date August 17, 2020
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03625401 - Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease Phase 2
Recruiting NCT05983575 - A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease Phase 3
Completed NCT05989087 - The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Recruiting NCT06080659 - Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity N/A
Not yet recruiting NCT06099587 - MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease N/A
Not yet recruiting NCT05604183 - Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease N/A
Withdrawn NCT03514875 - Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients N/A
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Completed NCT03706885 - Efavirenz for Patients With Alzheimer's Disease Phase 1
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Not yet recruiting NCT05006599 - SNIFF - 3-Week Aptar CPS Device Phase 2
Recruiting NCT02740634 - Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study N/A
Active, not recruiting NCT03069391 - The Interactive Physical and Cognitive Exercise System N/A
Recruiting NCT04701957 - The Ketogenic Diet for Alzheimer's Disease N/A
Recruiting NCT06268886 - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease Phase 2
Recruiting NCT04100889 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Recruiting NCT04656860 - Juice Plus Supplement Clinical Trial N/A
Recruiting NCT05315895 - The Dampness Syndrome of Chinese Medicine Cohort Study
Recruiting NCT04916964 - Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial) N/A
Recruiting NCT04804618 - Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease